Literature DB >> 22422597

Jugular and vagal paragangliomas: Systematic study of management with surgery and radiotherapy.

Carlos Suárez1, Juan P Rodrigo, Carsten C Bödeker, José L Llorente, Carl E Silver, Jeroen C Jansen, Robert P Takes, Primoz Strojan, Phillip K Pellitteri, Alessandra Rinaldo, William M Mendenhall, Alfio Ferlito.   

Abstract

BACKGROUND: The definitive treatment for head and neck paraganglioma (PG) is surgical excision. Unfortunately, surgery, particularly of vagal paraganglioma (VPG; "glomus vagale") and foramen jugulare ("glomus jugulare") tumors, may be complicated by injuries to the lower cranial nerves, a high price to pay for treatment for a benign tumor. Alternatively these tumors may be followed without treatment, or irradiated. The purpose of this review was to compare the existing evidence concerning the efficacy and safety of surgery, external beam radiotherapy (EBRT), and stereotactic radiosurgery (SRS), for jugular paragangliomas (JPGs) and VPGs.
METHODS: Relevant articles were reviewed using strict criteria for systematic searches. Forty-one surgical studies met the criteria which included 1310 patients. Twenty articles including 461 patients treated with EBRT, and 14 radiosurgery studies comprising 261 patients were also evaluated. Results were compared between treatment modalities using analysis of variance (ANOVA) tests.
RESULTS: A total of 1084 patients with JPGs and 226 VPGs were treated with different surgical procedures. Long-term control of the disease was achieved in 78.2% and 93.3% of patients, respectively. A total of 715 patients with JPG were treated with radiotherapy: 461 with EBRT and 254 with SRS. Control of the disease with both methods was obtained in 89.1% and 93.7% of the patients, respectively. The treatment outcomes of a JPG treated with surgery or radiotherapy were compared. Tumor control failure, major complication rates, and the number of cranial nerve palsies after treatment were significantly higher in surgical than in radiotherapy series. The results of SRS and EBRT in JPGs were compared and no significant differences were observed in tumor control. Because only 1 article reported on the treatment of 10 VPGs with radiotherapy, no comparisons with surgery could be made. Nevertheless, the vagus nerve was functionally preserved in only 11 of 254 surgically treated patients (4.3%).
CONCLUSION: There is evidence that EBRT and SRS offer a similar chance of tumor control with lower risks of morbidity compared with surgery in patients with JPGs. Although the evidence is based on retrospective studies, these results suggest that surgery should be considered only for selected cases, but the decision should be individual for every patient.
Copyright © 2012 Wiley Periodicals, Inc.

Entities:  

Keywords:  external beam radiotherapy; jugular paraganglioma; stereotactic radiosurgery; surgery; vagal paraganglioma

Mesh:

Year:  2012        PMID: 22422597     DOI: 10.1002/hed.22976

Source DB:  PubMed          Journal:  Head Neck        ISSN: 1043-3074            Impact factor:   3.147


  36 in total

1.  Modern trends in the management of head and neck paragangliomas.

Authors:  Carlos Suárez; Verónica Fernández-Alvarez; Hartmut P H Neumann; Carsten C Boedeker; Christian Offergeld; Alessandra Rinaldo; Primož Strojan; Alfio Ferlito
Journal:  Eur Arch Otorhinolaryngol       Date:  2015-12       Impact factor: 2.503

Review 2.  The Management of Locally Invasive Primary Thyroid Paraganglioma: A Case Report and Review of the Literature.

Authors:  L Navaratne; R G Mathew; G Kousparos; A McCombe
Journal:  Head Neck Pathol       Date:  2016-07-20

3.  Stereotactic radiosurgery of glomus jugulare tumors: current concepts, recent advances and future perspectives.

Authors:  Omer Sager; Ferrat Dincoglan; Murat Beyzadeoglu
Journal:  CNS Oncol       Date:  2015

4.  Age and Tumor Volume Predict Growth of Carotid and Vagal Body Paragangliomas.

Authors:  Berdine L Heesterman; Lisa M H de Pont; Berit M Verbist; Andel G L van der Mey; Eleonora P M Corssmit; Frederik J Hes; Peter Paul G van Benthem; Jeroen C Jansen
Journal:  J Neurol Surg B Skull Base       Date:  2017-07-31

Review 5.  Endocrine tumors associated with the vagus nerve.

Authors:  Arthur Varoquaux; Electron Kebebew; Fréderic Sebag; Katherine Wolf; Jean-François Henry; Karel Pacak; David Taïeb
Journal:  Endocr Relat Cancer       Date:  2016-07-12       Impact factor: 5.678

Review 6.  Current approaches and recent developments in the management of head and neck paragangliomas.

Authors:  David Taïeb; Alexandre Kaliski; Carsten C Boedeker; Victoria Martucci; Tito Fojo; John R Adler; Karel Pacak
Journal:  Endocr Rev       Date:  2014-07-17       Impact factor: 19.871

Review 7.  Molecular imaging and radionuclide therapy of pheochromocytoma and paraganglioma in the era of genomic characterization of disease subgroups.

Authors:  David Taïeb; Abhishek Jha; Giorgio Treglia; Karel Pacak
Journal:  Endocr Relat Cancer       Date:  2019-11       Impact factor: 5.678

8.  Observation and partial targeted surgery in the management of tympano-jugular paraganglioma: a contribution to the multioptional treatment.

Authors:  Antonio Mazzoni; Elisabetta Zanoletti
Journal:  Eur Arch Otorhinolaryngol       Date:  2015-03-31       Impact factor: 2.503

9.  Tumor multifocality with vagus nerve involvement as a phenotypic marker of SDHD mutation in patients with head and neck paragangliomas: A 18 F-FDOPA PET/CT study.

Authors:  Vincent Amodru; Pauline Romanet; Ugo Scemama; Marion Montava; Nicolas Fakhry; Frédéric Sebag; Frédéric Castinetti; Jean-Pierre Lavieille; Anderson Loundou; Arthur Varoquaux; Anne Barlier; Karel Pacak; David Taïeb
Journal:  Head Neck       Date:  2018-12-24       Impact factor: 3.147

10.  Carotid body paragangliomas: a systematic study on management with surgery and radiotherapy.

Authors:  Carlos Suárez; Juan P Rodrigo; William M Mendenhall; Marc Hamoir; Carl E Silver; Vincent Grégoire; Primož Strojan; Hartmut P H Neumann; Rupert Obholzer; Christian Offergeld; Johannes A Langendijk; Alessandra Rinaldo; Alfio Ferlito
Journal:  Eur Arch Otorhinolaryngol       Date:  2013-02-19       Impact factor: 2.503

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.